Engine of Change — your metabolic lane.

Metabolic autonomy for the cycle-shift arc — across perimenopause, across hormonal transitions, across the years the commercial “women’s wellness” aisle hands us very little evidence for. Five strains, sequenced at their designation loci, shipped at the human-trial window. *B. animalis* HN019 · *B. animalis* B420 · *L. rhamnosus* GG · *A. muciniphila* AH39 (80% pasteurised / 20% live) · *C. butyricum* 10. Structure-function support for healthy glucose metabolism and a balanced gut-microbiome metabolic axis — the gut-bound layer of cycle resilience everybody keeps leaving to the endocrinologists. 22 B CFU + 500 M TFU per capsule at manufacture.

See the strain list Press & wholesale

metabolic & insulin

Pharmacist-selectedRebel Flora

Engine of Change

Five-strain metabolic stack — B. animalis HN019 · B. animalis B420 · L. rhamnosus GG · A. muciniphila AH39 (80% pasteurised / 20% live) · C. butyricum 10. One of the most-studied probiotic organisms ever deposited in a culture collection, sequenced on every batch and printed on every panel.

CFU dose: 22 B CFU + 500 M TFU per capsule at manufacture (10 B CFU HN019 + 10 B CFU B420 + 2 B CFU LGG + 500 M TFU AH39 + 30 M CFU C. butyricum 10) — 1 capsule per serving, delivered in a digestive-resistant vegetarian capsule
At time of: Manufacture (printed at fill)
Strain ID: HN019 · B420 · GG · AH39 · CB10

Pharmacist brief

Read like a clinician, not a marketer.

The four blocks below reproduce what the pharmacist writes on the brief — strain designations (HN019 · B420 · GG · AH39 · CB10), citation trail anchored to Depommier 2019 and Stenman 2016, narrative rationale per organism, and the lane boundaries Engine of Change is honest about. The gut-metabolic axis is a women’s-health surface, and the panel lands at the dose the human trials used.

Pharmacist rationale

Why this strain, this dose, this panel.

Engine of Change ships a five-strain stack selected for the metabolic lane through a women's-health lens. B. animalis B420 and HN019 anchor the formula at 10 B CFU each: B420 is supported by Stenman 2016 (EBioMedicine) for healthy body composition and gut-barrier function at a metabolic scale; HN019 at matched dose by Cheng 2021 (Front Nutr) for bowel regularity and healthy gut-immune interaction. L. rhamnosus GG at 2 B CFU adds established microbiota-diversity and gut-barrier evidence. A. muciniphila AH39 at 500 M TFU is the formula's dual-action Akkermansia layer — 80% pasteurised cells tied to Depommier 2019 (Nat Med) for healthy glucose-metabolism markers, and 20% live cells for complementary microbiota diversity and gut-barrier activity. C. butyricum 10 at 30 M CFU rounds out the stack as the formula's butyrate-producer anchor, supporting colonocyte health and healthy inflammatory markers. Every organism holds to the published trial dose window. No stacking above it. Metabolic autonomy is the straight reading of the brief.

Counterculture Rx clinical pharmacist · strain brief

Clinical evidence

The primary studies behind this strain.

The dosing window is anchored to the peer-reviewed work below. Every row is identifiable by DOI and resolves to a primary source — no white-paper or QR code behind a marketing wall.

Citation 01Pasteurised Akkermansia muciniphila increases gut microbiota richness and regulates glucose metabolism in overweight or obese adults: results from a randomised, double-blind, placebo-controlled trial
Nature MedicineDepommier C., Everard A., Druart C., Plovier H., Van Hul M., Vieira-Silva S., Falony G., Raes J., Maiter D., Delzenne N. M., de Barsy M., Loumaye A., Hermans M. P., Thissen J. P., de Vos W. M., Cani P. D.
2019doi:10.1038/s41591-019-0495-2
Citation 02Probiotic with or without fibre controls body fat mass, associated with serum zonulin, in overweight and obese adults: randomised controlled trial
EBioMedicineStenman L. K., Lehtinen M. J., Meland N., Christensen J. E., Yeung N., Saarinen M. T., Courtney M., Burcelin R., Lähteenmäki-Uutela A., Cheng J., Rautonen N., Uusitupa H. M., Tiihonen K.
2016doi:10.1016/j.ebiom.2016.10.036
Citation 03Beneficial effects of Bifidobacterium animalis subsp. lactis 420 on human gut microbiota, gut barrier, and inflammatory markers: a randomised double-blind, placebo-controlled trial
NutrientsUusitupa H. M., Rasinkangas P., Lehtinen M. J., Mäkelä S. M., Airaksinen K., Anglenius H., Ouwehand A. C., Maukonen J.
2020doi:10.3390/nu12040892
Citation 04Bifidobacterium animalis subsp. lactis HN019 effects on gut health: a review
Frontiers in NutritionCheng J., Laitila A., Ouwehand A. C.
2021doi:10.3389/fnut.2021.790561

Story behind the SKU

Why this stack and these doses

The metabolic probiotic market is crowded with single-strain products at undisclosed doses, blended CFU that can't be attributed to any organism, and structure-function claims that reach past the published human-trial evidence. Engine of Change competes on designation transparency, not dose scale. We frame the metabolic lane as a women’s-health lane — because the gut-metabolic axis is part of the cycle arc, and perimenopause and hormonal shifts are routinely handed to women as a problem of willpower rather than a problem of evidence.

B. animalis B420 and HN019 anchor the formula at 10 B CFU each. B420 is supported by Stenman 2016 (EBioMedicine) for healthy body composition and healthy gut-barrier function at the metabolic dose window; HN019 at matched dose by Cheng 2021 (Front Nutr) and Uusitupa 2020 (Nutrients) for bowel regularity, healthy gut-immune interaction, and healthy inflammatory markers. L. rhamnosus GG at 2 B CFU brings established microbiota-diversity and gut-barrier evidence that complements the Bifidobacterium axis.

A. muciniphila AH39 at 500 M TFU is the formula's dual-action Akkermansia layer. The 80 % pasteurised fraction is tied to the Depommier 2019 human trial (Nat Med, 25 overweight adults, 12 weeks) for healthy glucose-metabolism markers and healthy body composition. The 20 % live-cell fraction adds complementary microbiota-diversity and short-chain fatty acid activity. We ship both forms together deliberately — the evidence base for the pasteurised form (Depommier 2019) and for the live form (Ashrafian 2021, Sci Rep) address complementary mechanisms, and the combined dose holds to the trial windows for each.

C. butyricum 10 rounds out the stack at 30 M CFU as the formula's butyrate-producer anchor. Butyrate is the primary energy substrate for colonocytes and a key modulator of the gut-lining environment; C. butyricum 10 contributes to healthy inflammatory markers and supports gut-barrier function through SCFA production. We name it on the panel because it is one of the why-our-bottles-talk-this-way threads: gut-barrier integrity, cycle resilience, the immune groundedness that the rest of the formula leans on.

Every organism holds to its published dose window. No artificial stacking above it.

What it is for

Engine of Change is the metabolic-lane SKU, framed for the cycle arc. Structure-function, line by line:

Healthy glucose metabolism — anchored to A. muciniphila AH39 (Depommier 2019) and B. animalis B420 (Stenman 2016). The post-prandial glucose response is a women’s-health marker long before it is a metabolic one.
Healthy body composition support — B420 body-composition evidence paired with AH39's dual metabolic-axis activity. The frame is resilience across cycle shifts, not “weight loss” as the male-default wellness aisle defines it.
Gut-barrier integrity — HN019, B420, LGG, and the AH39 live fraction in combination support a healthy intestinal barrier.
Balanced gut microbiome — LGG + AH39 live + C. butyricum butyrate production for microbial diversity and a healthy short-chain fatty acid environment.
Healthy inflammatory markers — C. butyricum 10 + HN019 + B420 SCFA and barrier mechanisms. The literature ties the gut-metabolic axis to the cycle arc the perimenopausal community has been mapping in plain language for years.

The panel says what it can do. Engine of Change is a dietary supplement providing normal structural and functional support for the metabolic-microbiome axis. It does not claim to treat, cure, diagnose, or prevent any disease.

How we verify each lot

Whole-genome sequencing at all five strain loci — HN019 / B420 / GG / AH39 / C. butyricum 10 on every batch. Drift against the strain-reference panel is a fail.
CFU plate count at the moment of fill for the four live strains — HN019, B420, LGG, and C. butyricum 10 are each counted and printed individually. The total is the sum of four per-organism counts, not an aggregate.
TFU viability assay for the AH39 component — confirming the 80 % pasteurised / 20 % live cell ratio and the 500 M TFU target at fill. The ratio is verified by viability assay, not assumed.
Pasteurisation-hold verification on the AH39 pasteurised fraction — temperature-hold parameters confirmed by thermal-cycled assay on every lot. Integrity of the outer-membrane proteins that the Depommier 2019 glucose-metabolism evidence depends on is verified by plate count after hold.

None of these methods are proprietary.

When Engine of Change is the wrong choice

If the goal is post-antibiotic GI reseeding at the close of an antibiotic course, Sovereign V is the lane — a multi-genus vaginal-and-gut anchor that also speaks to the GI flora. If the goal is a multi-genus seven-strain daily GI foundation covering the microbiome / immune / digestive axes across the full gut, CounterStrike is the lane. Engine of Change is the five-strain metabolic stack for the cycle-shift arc, and it does not substitute for what Sovereign V or CounterStrike do better. A pharmacist will tell you so directly.